Exploring new treatment options for refractory or relapsed acute myeloid leukemia
Official title: Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia
Run by Institute of Hematology & Blood Diseases Hospital, China · NCT06265545 · Data updated 2026-11-12
This study is testing different treatment options for people with stubborn or returning acute myeloid leukemia to see which ones work best for them.
Quick facts
| Study type | Interventional |
|---|---|
| Sex | All |
| Enrollment | 458 (estimated) |
| Sponsor | Institute of Hematology & Blood Diseases Hospital, China Academic / other |
| Locations | 1 site (Tianjin) |
| Status | Recruiting |
| Started | February 22, 2024 |
| Main results expected | January 30, 2028 |
| Study ends | June 30, 2028 |
| Registry record updated | August 7, 2026 |
| Trial ID | NCT06265545 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients diagnosed with refractory or relapsed acute myeloid leukemia who meet specific genetic and treatment criteria.
✕Probably not a fit
Patients with acute promyelocytic leukemia or those who have not experienced morphological recurrence of AML may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial aims to identify the most effective therapeutic strategies for patients with refractory or relapsed acute myeloid leukemia (AML). It employs a multicenter, platform-type approach to evaluate various salvage treatment regimens, assessing overall response rates, tolerability, and survival outcomes. Patients will be screened for specific genetic mutations and assigned to different treatment arms based on their individual conditions and previous treatments. The study includes a range of interventions, including targeted therapies and chemotherapy combinations.
Why it matters
Potential benefit: If successful, this study could provide new, effective treatment options for patients with difficult-to-treat AML.
How similar studies have gone: Other studies have shown promise with targeted therapies in AML, but this specific platform approach is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1\. Patients with acute myeloid leukemia (except for acute promyelocytic leukemia) diagnosed by bone marrow cell morphology, immunology and genetics above are classified according to the French-British-American Collaboration diagnostic criteria (FAB criteria) and the World Health Organization diagnostic criteria (WHO2016 criteria). 2\. Meet criteria for refractory/recurrent AML (except APL). The recurrence was morphological recurrence, excluding molecular recurrence. Except for simple extramedullary leukemia. 3\. Age and gender are not limited. 4. Informed consent must be signed before the start of the study procedure, and the informed consent must be signed by the patient himself or his immediate family if he is 18 years old and above; For young patients under the age of 18, the legal guardian shall sign the informed consent. Considering the patient's condition, if the patient's signature is not conducive to the treatment of the condition, the informed consent shall be signed by the legal guardian or the patient's immediate family. Exclusion Criteria: 1. Concurrent malignant tumors of other organs (patients requiring treatment). 2. Participants considered unsuitable for inclusion by the researchers.
Where it's running
-
Blood Hospital
Tianjin, China Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Testing a new CAR-T therapy for multiple myeloma
This study is testing a new CAR-T therapy for people with hard-to-treat multiple myeloma to see how safe it is and what the best dose is.
-
6MW5311 in adults with relapsed or refractory blood cancers
This study tests increasing doses of 6MW5311 in adults with multiple myeloma, AML, or CMML to see if it is safe and tolerable and to find a suitable dose for later studies.
-
CRD3874-SI in People with Leukemia
A small early-stage study tests CRD3874-SI to see if it is safe for adults with relapsed or refractory acute myeloid leukemia.
-
Allogeneic CAR-T CT0890B for relapsed/refractory AML
This study tests whether a universal CAR-T cell therapy called CT0890B is safe and potentially effective for adults with relapsed or refractory acute myeloid leukemia who express NKG2D ligands.
-
Biomarkers in Bone Marrow to Predict AML Chemosensitivity
This study tests whether markers in bone marrow can predict how adults with AML will respond to chemotherapy.
-
Azacitidine plus venetoclax maintenance vs azacitidine alone in AML
This trial tests whether adding venetoclax to azacitidine maintenance helps people with AML stay disease-free after achieving first remission.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.